 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning Celgene Corporation
|
-
Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID combined with IPH 2101
(19 Nov 2009)
Innate Pharma announced that Celgene Corporationhas agreed to collaborate with Innate Pharma to evaluate the potential clinical synergy of the combination treatment regimen of lenalidomide (REVLIMIDŽ) plus IPH 2101 in patients with multiple myeloma ...
-
Celgene Announces New Drug Application Filing for REVLIMID in Japan
(08 Jul 2009)
Celgene International Sārl announced it has filed a New Drug Application (NDA) with the Japanese Ministry of Health, Labour and Welfare (MHLW) for REVLIMID (lenalidomide) in combination with dexamethasone for the treatment of patients with multiple ...
-
Two major Phase III studies report oral Revlimid(R) (lenalidomide) plus dexamethasone shows increased overall survival advantage
(26 Nov 2007)
The New England Journal of Medicine published updated data from two Phase III studies that showed a combination treatment of oral lenalidomide plus dexamethasone increased overall survival and slowed disease progression in previously treated ...
-
Celgene Corporation Elects Sol J. Barer, Ph.D. to Chairman of the Board
(04 Jan 2007)
Celgene Corporation announced that its Board of Directors elected Sol J. Barer, Ph.D., Chief Executive Officer, to the additional position of Chairman of the Board, effective immediately. Dr. Barer has been Chief Executive Officer since May 1, 2006, ...
-
LifebankUSA(TM) Announces New Service to Bank Placental-Derived Stem Cells
(20 Apr 2006)
LifebankUSA, a subsidiary of Celgene Cellular Therapeutics (CCT), announced plans for a new service to bank stem cells derived from the placenta. Placental-derived stem cells (PDSCs), which have different characteristics from those isolated from ...
-
Celgene Corporation Reports Pluripotent Stem Cells Isolated From Placenta
(18 Apr 2005)
Celgene Corporation announced that human placenta-derived stem cells that are "pluripotent", or have the ability to become different types of tissue, can be isolated with a proprietary perfusion technology from placentas so they are available for ...
-
Celgene Corporation Reviews 2004 Achievements and Announces 2005 Financial Outlook
(11 Jan 2005)
Celgene Corporation today reviewed its clinical and commercial progress in 2004 and provided its initial outlook for 2005 at the J.P. Morgan 23rd Annual Healthcare Conference.In 2004, Celgene achieved outstanding results in its commercial ...
Additional information
Celgene Corporation
Summit, N.J., USA
Company
|
|
|
|
|
|
Top
